These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35822422)

  • 21. Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.
    Højberg PV; Vilsbøll T; Zander M; Knop FK; Krarup T; Vølund A; Holst JJ; Madsbad S
    Diabet Med; 2008 Nov; 25(11):1268-75. PubMed ID: 19046215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin and glucagon secretion are suppressed equally during both hyper- and euglycemia by moderate hyperinsulinemia in patients with diabetes mellitus.
    Murayama Y; Kawai K; Watanabe Y; Yoshikawa H; Yamashita K
    J Clin Endocrinol Metab; 1989 May; 68(5):925-31. PubMed ID: 2654170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus. Role of hepatic and extrahepatic tissues.
    Firth RG; Bell PM; Marsh HM; Hansen I; Rizza RA
    J Clin Invest; 1986 May; 77(5):1525-32. PubMed ID: 3517067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impaired crosstalk between pulsatile insulin and glucagon secretion in prediabetic individuals.
    Rohrer S; Menge BA; Grüber L; Deacon CF; Schmidt WE; Veldhuis JD; Holst JJ; Meier JJ
    J Clin Endocrinol Metab; 2012 May; 97(5):E791-5. PubMed ID: 22399501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GLP-1 Restores Altered Insulin and Glucagon Secretion in Posttransplantation Diabetes.
    Halden TA; Egeland EJ; Åsberg A; Hartmann A; Midtvedt K; Khiabani HZ; Holst JJ; Knop FK; Hornum M; Feldt-Rasmussen B; Jenssen T
    Diabetes Care; 2016 Apr; 39(4):617-24. PubMed ID: 26908914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of glucagon response on early postprandial glucose excursions irrespective of residual β-cell function in type 1 diabetes: A cross-sectional study using a mixed meal tolerance test.
    Ito A; Horie I; Miwa M; Sako A; Niri T; Nakashima Y; Shigeno R; Haraguchi A; Natsuda S; Akazawa S; Kamada A; Kawakami A; Abiru N
    J Diabetes Investig; 2021 Aug; 12(8):1367-1376. PubMed ID: 33369175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics.
    Baron AD; Schaeffer L; Shragg P; Kolterman OG
    Diabetes; 1987 Mar; 36(3):274-83. PubMed ID: 2879757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of lack of suppression of glucagon on glucose tolerance in humans.
    Shah P; Basu A; Basu R; Rizza R
    Am J Physiol; 1999 Aug; 277(2):E283-90. PubMed ID: 10444424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impaired Suppression of Glucagon in Obese Subjects Parallels Decline in Insulin Sensitivity and Beta-Cell Function.
    Chen X; Maldonado E; DeFronzo RA; Tripathy D
    J Clin Endocrinol Metab; 2021 Apr; 106(5):1398-1409. PubMed ID: 33524152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glycemic control determines hepatic and peripheral glucose effectiveness in type 2 diabetic subjects.
    Hawkins M; Gabriely I; Wozniak R; Reddy K; Rossetti L; Shamoon H
    Diabetes; 2002 Jul; 51(7):2179-89. PubMed ID: 12086948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
    Degn KB; Juhl CB; Sturis J; Jakobsen G; Brock B; Chandramouli V; Rungby J; Landau BR; Schmitz O
    Diabetes; 2004 May; 53(5):1187-94. PubMed ID: 15111485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes.
    Kashyap S; Belfort R; Gastaldelli A; Pratipanawatr T; Berria R; Pratipanawatr W; Bajaj M; Mandarino L; DeFronzo R; Cusi K
    Diabetes; 2003 Oct; 52(10):2461-74. PubMed ID: 14514628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Islet hormone secretion in pancreatic cancer patients with diabetes.
    Permert J; Larsson J; Fruin AB; Tatemoto K; Herrington MK; von Schenck H; Adrian TE
    Pancreas; 1997 Jul; 15(1):60-8. PubMed ID: 9211494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
    Nauck MA; Kleine N; Orskov C; Holst JJ; Willms B; Creutzfeldt W
    Diabetologia; 1993 Aug; 36(8):741-4. PubMed ID: 8405741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Both fasting glucose production and disappearance are abnormal in people with "mild" and "severe" type 2 diabetes.
    Basu R; Schwenk WF; Rizza RA
    Am J Physiol Endocrinol Metab; 2004 Jul; 287(1):E55-62. PubMed ID: 14982753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
    Hare KJ
    Dan Med Bull; 2010 Sep; 57(9):B4181. PubMed ID: 20816021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus.
    Shapiro ET; Van Cauter E; Tillil H; Given BD; Hirsch L; Beebe C; Rubenstein AH; Polonsky KS
    J Clin Endocrinol Metab; 1989 Sep; 69(3):571-6. PubMed ID: 2503533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperglucagonemia in Pediatric Adiposity Associates With Cardiometabolic Risk Factors but Not Hyperglycemia.
    Stinson SE; Jonsson AE; de Retana Alzola IF; Lund MAV; Frithioff-Bøjsøe C; Aas Holm L; Fonvig CE; Pedersen O; Ängquist L; Sørensen TIA; Holst JJ; Christiansen M; Holm JC; Hartmann B; Hansen T
    J Clin Endocrinol Metab; 2022 May; 107(6):1569-1576. PubMed ID: 35213713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperglucagonemia Does Not Explain the β-Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study.
    Kahn SE; Mather KJ; Arslanian SA; Barengolts E; Buchanan TA; Caprio S; Ehrmann DA; Hannon TS; Marcovina S; Nadeau KJ; Utzschneider KM; Xiang AH; Edelstein SL; ;
    Diabetes Care; 2021 Sep; 44(9):1961-1969. PubMed ID: 34131047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.